Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1022-1026. doi: 10.19723/j.issn.1671-167X.2018.06.014

• Article • Previous Articles     Next Articles

Comparison of disease activities and extent measurements for anti-neutrophil cytoplasmic autoantibody-associated vasculitis

Sheng-guang LI1,(),Qing ZHANG2,Hui-qiong ZHOU2   

  1. 1. Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China
    2. Department of Rheumatology, Fouth Medical Center of PLA General Hospital, Beijing 100048, China
  • Received:2018-07-09 Online:2018-12-18 Published:2018-12-18
  • Contact: Sheng-guang LI E-mail:lishengguang@vip.sina.com

Abstract:

Objective: To investigate the significance of a set of seven disease activities and extension measurements and their correlations between one and another for anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV).Methods:A total of 121 patients from Peking University International Hospital and Fouth Medical Center of PLA General Hospital with confirmed diagnoses of AAV clinically were enrolled in the study, including 15 cases of eosinophilic granulomatous with polyangiitis (EGPA), 59 cases of granulomatous with polyangiitis (GPA) and 47 cases of microscopic polyangiitis (MPA). A hundred and twenty-one AAV patients were divided into death group and survival group according to their survival conditions. A set of seven disease assessment scales including Birmingham vasculitis activity score (BVAS)-1994, BVAS-2003, as well as BVAS/GPA, vasculitis damage index (VDI), disease extent index (DEI), five factor score (FFS)-1996, and FFS-2009 were measured and scored one by one, and their relationships which were represented by Spearman correlation coefficient were compared between one and another.Results:BVAS-1994, BVAS-2003, as well as BVAS/GPA, VDI, DEI, and FFS, all of those seven evaluation indexes of the AAV patients in the death group were significantly higher than those in the survival group (P<0.05). Except for BVAS/GPA, all those above indicators in the patients with EGPA were lower than those in the patients with GPA and those in the patients with MPA, and those in all of the AAV patients as a whole group. There were high correlations among BVAS-2003, BVAS-1994 and BVAS/GPA (r values were 0.9 and 0.7, respectively); BVAS-1994 was fairly correlated with BVAS/GPA (r=0.69); FFS-1996 and FFS-2009 were highly correlated (r=0.73) with each other; BVAS-1994, BVAS-2003 and BVAS/GPA were fairly correlated with DEI (with r values of 0.62, 0.65, and 0.62, respectively); VDI was also fairly correlated with BVAS-1994 and with BVAS-2003 (r values were 0.49 and 0.52, respectively).Conclusion:All of those seven AAV assessment indicators above can be used as indicators of disease activity and prognosis in AAV patients, most of which were relevant within one and another. There were high correlations among BVAS-2003, BVAS-1994 and BVAS/GPA, and besides, there were also high correlations between FFS-1996 and FFS-2009.

Key words: Anti-neutrophil cytoplasmic antibody-associated vasculitis, Prognosis, Disease activities

CLC Number: 

  • R593.9

Table 1

Applications of AAV disease evaluation indexes in different types of AAV classifications (x-±s)"

Items EGPA (n=15) MPA (n=47) GPA (n=59) AAV (n=121)
BVAS-1994 16.2±8.4 23.5±6.0* 23.3±9.4* 22.5±8.4*
BVAS-2003 16.9±7.7 22.4±6.8* 22.8±9.8* 21.9±8.6*
VDI 3.1±2.5 4.2±2.5 4.0±2.4 4.0±2.5
DEI 8.2±3.1 7.8±2.8 8.9±3.2 8.4±3.0
FFS-1996 0.1±0.4 1.5±1.1* 0.9±1.0* 1.0±1.1*#
FFS-2009 0.1±0.4 1.4±0.9* 1.0±1.0*# 1.1±1.0*#

Table 2

Comparison of seven disease indicators in AAV patients"

Items Death group (n=25) Survival group (n=96) t P
Age/years 69±11 60±16 2.8 0.006
BVAS-1994 26.2±7.5 21.0±8.5 2.8 0.006
BVAS-2003 26.9±8.3 20.0±8.8 3.5 0.001
BVAS/GPA 8.3±4.9 5.9±2.9 2.2 0.031
VDI 5.8±2.4 3.5±2.2 4.6 <0.001
DEI 9.5±3.5 8.0±2.8 2.2 0.028
FFS-1996 1.5±1.2 0.9±1.0 2.7 0.008
FFS-2009 1.8±1.1 0.9±0.9 4.0 <0.001

Table 3

Spearman correlation coefficient of 7 AAV disease assessment scales"

Items BVAS-1994 BVAS-2003 BVAS/GPA VDI DEI FFS-1996 FFS-2009
BVAS-1994 1
BVAS-2003 0.90* 1
BVAS/GPA 0.69* 0.70* 1
VDI 0.49* 0.52* 0.37* 1
DEI 0.62* 0.65* 0.62* 0.37* 1
FFS-1996 0.44* 0.45* 0.23 0.31* 0.30* 1
FFS-2009 0.38* 0.39* 0.09 0.28* 0.23# 0.73* 1
[1] Jennette JC, Falk RJ, Bacon PA , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides[J]. Arthritis Rheum, 2013,65(1):1-11.
doi: 10.1002/art.37715 pmid: 23045170
[2] Yates M, Watts RA, Bajema IM , et al. EULAR/ERA-EDTA re-commendations for the management of ANCA-associated vasculitis[J]. Ann Rheum Dis, 2016,75(9):1583-1594.
[3] Lanham JG, Elkon KB, Pusey CD , et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome[J]. Medicine, 1984,63(2):65-81.
doi: 10.1097/00005792-198403000-00001
[4] Masi AT, Hunder GG, Lie JT , et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)[J]. Arthritis Rheum, 1990,33(8):1094-1100.
doi: 10.1002/art.1780330806 pmid: 2202307
[5] Leavitt RY, Fauci AS, Bloch DA , et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis[J]. Arthritis Rheum, 1990,33(8):1101-1107.
[6] Watts R, Lane S, Hanslik T , et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiolo-gical studies[J]. Ann Rheum Dis, 2007,66(2):222-227.
[7] Luqmani RA, Bacon PA, Moots RJ , et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis[J]. QJM, 1994,87(11):671.
[8] Eisenberger U, Fakhouri F, Vanhille P , et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome[J]. Nephrol Dial Transplant, 2005,20(7):1392-1399.
doi: 10.1093/ndt/gfh830
[9] Stone JH, Hoffman GS, Merkel PA , et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham vasculitis activity score[J]. Arthritis Rheum, 2001,44(4):912-920.
doi: 10.1002/(ISSN)1529-0131
[10] Exley AR, Bacon PA, Luqmani RA , et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides[J]. Arthritis Rheum, 2014,40(2):371-380.
doi: 10.1002/art.1780400222 pmid: 9041949
[11] De GK, Gross WL, Herlyn K , et al. Development and validation of a disease extent index for Wegener’s granulomatosis[J]. Clin Nephrol, 2001,55(1):31-38.
pmid: 11200865
[12] Guillevin L, Lhote F, Gayraud M , et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients[J]. Medicine, 1996,75(1):17-28.
doi: 10.1097/00005792-199601000-00003
[13] Guillevin L, Pagnoux C, Seror R , et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort[J]. 2011,90(1):19-27.
doi: 10.1097/MD.0b013e318205a4c6 pmid: 21200183
[14] Moiseev S, Novikov P, Jayne D , et al. End-stage renal disease in ANCA-associated vasculitis[J]. Nephrol Dial Transplant, 2017,32(2):248-253.
doi: 10.1093/ndt/gfw046 pmid: 27190338
[15] Greenan K, Vassallo D, Chinnadurai R , et al. Respiratory manifestations of ANCA-associated vasculitis[J]. Clin Respir J, 2018,12(1):57-61.
doi: 10.1111/crj.12478 pmid: 27059787
[16] Frausova D, Hruskova Z, Lanska V , et al. Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study[J]. Arthritis Res Ther, 2016(18):168.
doi: 10.1186/s13075-016-1055-5 pmid: 4944267
[17] 张清, 周惠琼, 郭娟 , 等. 抗中性粒细胞胞质抗体相关性血管炎死亡危险因素的探讨[J]. 中华医学杂志, 2017,97(43):3392-3395.
[1] Fei WANG,Xiang ZHU,Bei HE,Hong ZHU,Ning SHEN. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200.
[2] Wei-bo GAO,Mao-jing SHI,Hai-yan ZHANG,Chun-bo WU,Ji-hong ZHU. Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 921-927.
[3] Mei-xiang ZHANG,Wen-zhi SHI,Jian-xin LIU,Chun-jian WANG,Yan LI,Wei WANG,Bin JIANG. Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 915-920.
[4] Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863.
[5] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[6] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[7] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[8] CHEN Huai-an,LIU Shuo,LI Xiu-jun,WANG Zhe,ZHANG Chao,LI Feng-qi,MIAO Wen-long. Clinical value of inflammatory biomarkers in predicting prognosis of patients with ureteral urothelial carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 302-307.
[9] Shi-bo LIU,Hui GAO,Yuan-chun FENG,Jing LI,Tong ZHANG,Li WAN,Yan-ying LIU,Sheng-guang LI,Cheng-hua LUO,Xue-wu ZHANG. Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1069-1074.
[10] Wei-qian CHEN,Xiao-na DAI,Ye YU,Qin WANG,Jun-yu LIANG,Yi-ni KE,Cai-hong YI,Jin LIN. Analysis of clinical features and prognosis in patients with primary Sjögren’s syndrome and autoimmune liver disease [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 886-891.
[11] Ru MA,Xin-bao LI,Feng-cai YAN,Yu-lin LIN,Yan LI. Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 240-246.
[12] Wen-peng WANG,Jie-fu WANG,Jun HU,Jun-feng WANG,Jia LIU,Da-lu KONG,Jian LI. Clinicopathological features and prognosis of colorectal stromal tumor [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 353-361.
[13] Xiao WANG,Zhao-xing LI,Huan-fang FAN,Li-ying WEI,Xu-jin GUO,Na GUO,Tong WANG. A rare case of cystadenoma in the small intestine [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 382-384.
[14] Yu-qing OUYANG,Lian-fang NI,Xin-min LIU. Prognosis factors analysis of patients with malignant solitary pulmonary nodules [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 158-162.
[15] Yan-jin WANG,Xiao-yan XIE,Ying-ying HONG,Jia-ying BAI,Jian-yun ZHANG,Tie-jun LI. Clinicopathological analysis of 844 cases of odontogenic keratocysts [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 35-42.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 456 -458 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 125 -128 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 135 -140 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 158 -161 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 217 -220 .
[6] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 52 -55 .
[7] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 297 -301 .
[8] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 505 -515 .
[9] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 599 -601 .
[10] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 516 -520 .